Footprints of the EADV: a meeting report from the 17th Congress of the European Academy of Dermatology and Venereology

Abstract

The 17th Congress of the European Academy of Dermatology and Venereology took place in Paris on 17-20 September 2008 and brought together nearly 11,000 participants. Various plenary lectures, subspecialty meetings, 'free communications', 'top ten', 'test yourself' and 'junior' sessions, 19 courses and 14 'lunches with the expert', six forums, 27 symposia and 45 workshops were pressed into the 4 days of the meeting. Over 1700 posters were presented and exhibited. The themes of a number of symposiums, workshops and sessions overlapped, offering additional educational opportunities despite a very busy schedule. The meeting was well organized. Aesthetic dermatology comprised a significant part of the meeting. It is impossible to encompass all important presentations and we highlight a few medical pearls presented at the meeting; however, our report is not intended as a substitute for reading the conference proceedings and related references quoted in this article.

Updates from the British Association of Dermatologists 91st Annual Meeting, 5-7 July 2011, London, U.K.

“…The common motifs of the meeting, similarly to other recent conventions, appeared to be a trend of growing expectations; as the efficacy and number of available treatments are increasing, so are the goals and expectations rising 80 . For instance, if in the past physicians aspired simply to control psoriasis, they are now expected to clear it completely.…”

Psoriasis: an evidence-based update. Report of the 9th Evidenced Based Update Meeting, 12 May 2011, Loughborough, U.K.

“…However, the deficiencies in the evidence were clear to see: many trials are still relatively short with clinical and methodological heterogeneity, lack of effective treatments for nail psoriasis and PPP, a need for long‐term safety trials for various agents including potent and superpotent topical corticosteroids, as well as combination of biologics with phototherapy or other systemic treatments, and routine assessment of quality of life in trials with topical treatments. Numerous publications are currently produced in this field and it is hoped that with the aid of the Evidence Based Update Meeting and similar steering meetings the above deficiencies might be adequately addressed in due course 72–163 . The feedback from the delegates was very positive: 60% said the meeting was extremely useful and 39% useful.…”

Updates from the British Association of Dermatologists 89th Annual Meeting, 7-10 July 2009, Glasgow, U.K.

“…Because squamous cell carcinomas (SCCs) are the second most common skin cancer and an important cause of mortality and morbidity, especially in immunosuppressed patients, a considerable effort has gone into improving their diagnosis, pathogenesis and treatment 3,4,9–41 . Dr N. Mortimer and colleagues from Tauranga, New Zealand, reported on desmoplasia in a retrospective case series of 52 cutaneous SCCs, an under‐reported SCC variant 42 .…”